Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.45 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.38 |
| ▸ | HTR3A | P46098 | 2/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | F10 | P00742 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.36 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.36 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1002883 | 0.81 | PARP1 (0.47) | PARP1KCNH2PIK3CAPIK3CDPIK3CG | |
| SCHEMBL2025995 | 0.80 | GRM2 (0.55) | ITGB3ITGA2BTDP1CYP2D6HRH3 | |
| SCHEMBL1001176 | 0.78 | PARP1 (0.47) | PARP1 | |
| SCHEMBL1002672 | 0.76 | ACHE (0.53) | PARP1 | |
| SCHEMBL1000891 | 0.76 | PARP1 (0.45) | PARP1ITGB3ITGA2BPIK3CAPIK3CD | |
| SCHEMBL1001178 | 0.74 | PARP1 (0.37) | PARP1TDP1SLC6A2SLC6A4PIK3CA | |
| SCHEMBL8271584 | 0.73 | PIK3CD (0.42) | PARP1PIK3CAPIK3CDPIK3CGMAPK1 | |
| SCHEMBL13613670 | 0.73 | PIK3CD (0.42) | PARP1KCNH2PIK3CAPIK3CDPIK3CG | |
| SCHEMBL1001568 | 0.73 | PIK3CD (0.42) | PARP1KCNH2PIK3CAPIK3CDPIK3CG | |
| SCHEMBL1001933 | 0.73 | PIK3CG (0.42) | PARP1PIK3CAPIK3CDPIK3CGMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166155-A1 | Substituted Isoindolones and Their Use as Metabotropic Glutamate Receptor Potentiators | VAN WAGENEN BRADFORD | 2011-07-07 | — | — | US | disclosed |
| US-20110166155-A1 | Substituted Isoindolones and Their Use as Metabotropic Glutamate Receptor Potentiators | VAN WAGENEN BRADFORD | 2011-07-07 | — | — | US | disclosed |
| US-20110166155-A1 | Substituted Isoindolones and Their Use as Metabotropic Glutamate Receptor Potentiators | VAN WAGENEN BRADFORD | 2011-07-07 | — | — | US | disclosed |
| US-7868008-B2 | Substituted isoindolones and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2011-01-11 | — | — | US | disclosed |
| US-7868008-B2 | Substituted isoindolones and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2011-01-11 | — | — | US | disclosed |
| US-7868008-B2 | Substituted isoindolones and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2011-01-11 | — | — | US | disclosed |
| US-20090111830-A1 | SUBSTITUTED ISOINDOLONES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
| US-20090111830-A1 | SUBSTITUTED ISOINDOLONES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
| US-20090111830-A1 | SUBSTITUTED ISOINDOLONES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
| WO-2007021309-A1 | SUBSTITUTED ISOINDOLONES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111830-A1 | SUBSTITUTED ISOINDOLONES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | GRM1, GRIN1, GRM2 | PARP1 3651/4885ITGB3 4076/4885ITGA2B 3802/4885 |
| US-20110166155-A1 | Substituted Isoindolones and Their Use as Metabotropic Glutamate Receptor Potentiators | GRM1, GRIN1, GRM2 | PARP1 3651/4885ITGB3 4076/4885ITGA2B 3802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.